Krystal Accounts Payable vs Capital Surpluse Analysis

KRYS Stock

USD 160.05 1.55 0.96%

Krystal Biotech financial indicator trend analysis is infinitely more than just investigating Krystal Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krystal Biotech is a good investment. Please check the relationship between Krystal Biotech Accounts Payable and its Capital Surpluse accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Accounts Payable vs Capital Surpluse

Accounts Payable vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Krystal Biotech Accounts Payable account and Capital Surpluse. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Krystal Biotech's Accounts Payable and Capital Surpluse is 0.84. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Krystal Biotech, assuming nothing else is changed. The correlation between historical values of Krystal Biotech's Accounts Payable and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Krystal Biotech are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Accounts Payable i.e., Krystal Biotech's Accounts Payable and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Krystal Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Krystal Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Capital Surpluse

Most indicators from Krystal Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 3.24 in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.0M	34.3M	5.0M	6.2M
Interest Income	197K	5.2M	22.6M	23.8M

Depreciation And Amortization Interest Income

Krystal Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Retained Earnings Total Equity	Net Invested Capital
Total Assets		0.81	0.84	0.99	1.0	0.77	0.99	0.96	-0.93	-0.95	0.81	0.86	0.98	0.92	0.9	-0.73	0.82	0.99	0.98	0.99	0.98	0.97	1.0	0.97	-0.95	0.93
Short Long Term Debt Total	0.81		0.57	0.85	0.81	0.76	0.85	0.76	-0.85	-0.77	0.74	0.86	0.73	0.86	0.88	-0.38	0.74	0.84	0.85	0.8	0.84	0.75	0.83	0.73	-0.86	0.81
Other Current Liab	0.84	0.57		0.85	0.84	0.56	0.78	0.9	-0.62	-0.93	0.44	0.52	0.87	0.68	0.7	-0.8	0.64	0.82	0.84	0.87	0.84	0.91	0.82	0.92	-0.74	0.73
Total Current Liabilities	0.99	0.85	0.85		0.98	0.73	0.98	0.98	-0.89	-0.97	0.81	0.83	0.98	0.91	0.91	-0.68	0.86	0.99	0.98	0.99	1.0	0.98	0.98	0.98	-0.97	0.93
Total Stockholder Equity	1.0	0.81	0.84	0.98		0.77	0.99	0.96	-0.93	-0.95	0.8	0.87	0.98	0.92	0.9	-0.73	0.82	0.99	0.98	0.99	0.98	0.96	1.0	0.97	-0.95	0.93
Other Liab	0.77	0.76	0.56	0.73	0.77		0.8	0.67	-0.85	-0.69	0.62	0.83	0.66	0.8	0.82	-0.45	0.48	0.78	0.76	0.74	0.7	0.66	0.81	0.66	-0.76	0.71
Net Tangible Assets	0.99	0.85	0.78	0.98	0.99	0.8		0.96	-0.94	-0.94	0.87	0.89	0.96	0.95	0.94	-0.63	0.86	1.0	0.97	0.98	0.98	0.95	0.99	0.95	-0.98	0.95
Property Plant And Equipment Net	0.96	0.76	0.9	0.98	0.96	0.67	0.96		-0.81	-0.99	0.78	0.75	0.99	0.87	0.87	-0.68	0.87	0.97	0.94	0.98	0.98	1.0	0.94	1.0	-0.95	0.91
Net Debt	-0.93	-0.85	-0.62	-0.89	-0.93	-0.85	-0.94	-0.81		0.8	-0.81	-0.97	-0.85	-0.92	-0.91	0.6	-0.73	-0.92	-0.93	-0.9	-0.88	-0.81	-0.95	-0.81	0.89	-0.89
Retained Earnings	-0.95	-0.77	-0.93	-0.97	-0.95	-0.69	-0.94	-0.99	0.8		-0.72	-0.74	-0.96	-0.88	-0.89	0.66	-0.86	-0.96	-0.94	-0.97	-0.97	-0.99	-0.93	-0.99	0.94	-0.91
Accounts Payable	0.81	0.74	0.44	0.81	0.8	0.62	0.87	0.78	-0.81	-0.72		0.84	0.81	0.88	0.82	-0.27	0.86	0.84	0.74	0.78	0.82	0.77	0.79	0.75	-0.9	0.87
Cash	0.86	0.86	0.52	0.83	0.87	0.83	0.89	0.75	-0.97	-0.74	0.84		0.78	0.96	0.93	-0.41	0.76	0.87	0.87	0.83	0.83	0.74	0.89	0.74	-0.87	0.91
Non Current Assets Total	0.98	0.73	0.87	0.98	0.98	0.66	0.96	0.99	-0.85	-0.96	0.81	0.78		0.88	0.85	-0.72	0.85	0.98	0.94	0.98	0.98	0.99	0.96	0.99	-0.94	0.92
Cash And Short Term Investments	0.92	0.86	0.68	0.91	0.92	0.8	0.95	0.87	-0.92	-0.88	0.88	0.96	0.88		0.98	-0.43	0.88	0.94	0.91	0.91	0.91	0.87	0.93	0.86	-0.95	0.98
Common Stock Shares Outstanding	0.9	0.88	0.7	0.91	0.9	0.82	0.94	0.87	-0.91	-0.89	0.82	0.93	0.85	0.98		-0.42	0.87	0.93	0.91	0.9	0.9	0.86	0.92	0.85	-0.95	0.95
Long Term Debt Total	-0.73	-0.38	-0.8	-0.68	-0.73	-0.45	-0.63	-0.68	0.6	0.66	-0.27	-0.41	-0.72	-0.43	-0.42		-0.32	-0.66	-0.74	-0.73	-0.67	-0.69	-0.72	-0.73	0.51	-0.48
Non Current Liabilities Total	0.82	0.74	0.64	0.86	0.82	0.48	0.86	0.87	-0.73	-0.86	0.86	0.76	0.85	0.88	0.87	-0.32		0.86	0.81	0.85	0.88	0.87	0.8	0.84	-0.91	0.92
Capital Surpluse	0.99	0.84	0.82	0.99	0.99	0.78	1.0	0.97	-0.92	-0.96	0.84	0.87	0.98	0.94	0.93	-0.66	0.86		0.98	0.99	0.99	0.97	0.99	0.97	-0.98	0.94
Other Current Assets	0.98	0.85	0.84	0.98	0.98	0.76	0.97	0.94	-0.93	-0.94	0.74	0.87	0.94	0.91	0.91	-0.74	0.81	0.98		0.98	0.97	0.94	0.99	0.95	-0.93	0.91
Other Stockholder Equity	0.99	0.8	0.87	0.99	0.99	0.74	0.98	0.98	-0.9	-0.97	0.78	0.83	0.98	0.91	0.9	-0.73	0.85	0.99	0.98		0.99	0.98	0.99	0.98	-0.95	0.93
Total Liab	0.98	0.84	0.84	1.0	0.98	0.7	0.98	0.98	-0.88	-0.97	0.82	0.83	0.98	0.91	0.9	-0.67	0.88	0.99	0.97	0.99		0.98	0.97	0.98	-0.97	0.94
Property Plant And Equipment Gross	0.97	0.75	0.91	0.98	0.96	0.66	0.95	1.0	-0.81	-0.99	0.77	0.74	0.99	0.87	0.86	-0.69	0.87	0.97	0.94	0.98	0.98		0.94	1.0	-0.94	0.91
Total Current Assets	1.0	0.83	0.82	0.98	1.0	0.81	0.99	0.94	-0.95	-0.93	0.79	0.89	0.96	0.93	0.92	-0.72	0.8	0.99	0.99	0.99	0.97	0.94		0.95	-0.95	0.93
Property Plant Equipment	0.97	0.73	0.92	0.98	0.97	0.66	0.95	1.0	-0.81	-0.99	0.75	0.74	0.99	0.86	0.85	-0.73	0.84	0.97	0.95	0.98	0.98	1.0	0.95		-0.93	0.9
Retained Earnings Total Equity	-0.95	-0.86	-0.74	-0.97	-0.95	-0.76	-0.98	-0.95	0.89	0.94	-0.9	-0.87	-0.94	-0.95	-0.95	0.51	-0.91	-0.98	-0.93	-0.95	-0.97	-0.94	-0.95	-0.93		-0.95
Net Invested Capital	0.93	0.81	0.73	0.93	0.93	0.71	0.95	0.91	-0.89	-0.91	0.87	0.91	0.92	0.98	0.95	-0.48	0.92	0.94	0.91	0.93	0.94	0.91	0.93	0.9	-0.95

Click cells to compare fundamentals

Krystal Biotech Account Relationship Matchups

Krystal Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	209.0M	310.8M	626.3M	558.5M	818.4M	859.3M
Other Current Liab	19K	26K	87K	23.3M	27.5M	28.9M
Total Current Liabilities	3.3M	15.5M	25.7M	28.8M	33.1M	34.7M
Total Stockholder Equity	202.9M	292.1M	593.6M	522.2M	778.6M	817.6M
Net Tangible Assets	202.9M	292.1M	593.6M	522.2M	600.6M	630.6M
Property Plant And Equipment Net	11.2M	34.2M	119.6M	169.7M	168.2M	176.6M
Net Debt	(184.3M)	(256.7M)	(333.2M)	(153.0M)	(350.2M)	(332.7M)
Retained Earnings	(39.0M)	(71.2M)	(140.8M)	(280.8M)	(269.8M)	(256.3M)
Accounts Payable	724K	2.1M	8.4M	4.0M	4.1M	2.8M
Cash	187.5M	268.3M	341.2M	161.9M	358.3M	202.5M
Non Current Assets Total	13.1M	35.8M	184.0M	174.7M	230.4M	242.0M
Non Currrent Assets Other	1.5M	1.6M	74K	324K	263K	249.9K
Cash And Short Term Investments	193.7M	271.3M	438.1M	379.2M	532.2M	271.9M
Common Stock Shares Outstanding	15.9M	18.8M	22.2M	25.5M	27.8M	18.0M
Liabilities And Stockholders Equity	209.0M	310.8M	626.3M	558.5M	818.4M	859.3M
Non Current Liabilities Total	2.8M	3.3M	7.0M	7.4M	6.6M	4.0M
Capital Surpluse	133.2M	242.0M	363.3M	734.5M	844.7M	886.9M
Other Current Assets	2.2M	3.8M	4.2M	4.6M	6.7M	7.0M
Other Stockholder Equity	242.0M	363.3M	734.5M	803.7M	1.0B	1.1B
Total Liab	6.1M	18.8M	32.7M	36.2M	39.7M	41.7M
Property Plant And Equipment Gross	11.2M	34.2M	123.8M	176.5M	181.1M	190.1M
Total Current Assets	195.9M	275.1M	442.3M	383.8M	587.9M	617.3M
Accumulated Other Comprehensive Income	10K	6K	(163K)	(728K)	638K	669.9K
Property Plant Equipment	11.2M	30.9M	119.6M	169.7M	195.2M	204.9M
Other Assets	1.5M	4.9M	74K	324K	372.6K	354.0K
Short Term Investments	6.2M	3.0M	96.9M	217.3M	173.9M	182.5M
Net Invested Capital	202.9M	292.1M	593.6M	522.2M	778.6M	401.1M
Net Working Capital	192.6M	259.6M	416.5M	354.9M	554.8M	304.5M

Pair Trading with Krystal Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.

The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Krystal Biotech is a strong investment it is important to analyze Krystal Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Krystal Biotech's future performance. For an informed investment choice regarding Krystal Stock, refer to the following important reports:

How To Invest In Krystal

Details

Is Krystal Stock a good investment?

Details

What is Krystal Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Krystal Stock analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.

	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities

Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

2.18

Revenue Per Share

3.451

Return On Assets

(0.05)

Return On Equity

0.0887

The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Krystal Accounts Payable vs Capital Surpluse Analysis

Accounts Payable vs Capital Surpluse

Accounts Payable vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Accounts Payable

Capital Surpluse

Krystal Biotech fundamental ratios Correlations

Krystal Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Krystal Biotech fundamental ratios Accounts

Pair Trading with Krystal Biotech

Complementary Tools for Krystal Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity
Capital Surpluse	+ 1.0	Net Tangible Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Property Plant Equipment	- 0.99	Retained Earnings
Property Plant And Equipment Gross	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Property Plant And Equipment Net
Retained Earnings Total Equity	- 0.98	Capital Surpluse
Retained Earnings Total Equity	- 0.98	Net Tangible Assets
Retained Earnings Total Equity	- 0.97	Total Liab